Trevena Inc (TRVN) Short Interest Update

Trevena Inc (NASDAQ:TRVN) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 8,481,679 shares, a drop of 41.2% from the October 15th total of 14,428,796 shares. Based on an average trading volume of 3,940,966 shares, the days-to-cover ratio is presently 2.2 days. Approximately 14.2% of the shares of the stock are sold short.

A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research note on Thursday. HC Wainwright cut shares of Trevena from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $3.00 to $0.75 in a research note on Monday, November 5th. JMP Securities lifted their price objective on shares of Trevena from $4.00 to $15.00 and gave the company an “outperform” rating in a research note on Friday, October 12th. Needham & Company LLC cut shares of Trevena from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Finally, Jefferies Financial Group cut shares of Trevena from a “buy” rating to a “hold” rating and decreased their price objective for the company from $10.00 to $1.00 in a research note on Wednesday, October 10th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Trevena presently has an average rating of “Buy” and a consensus price target of $5.42.

Shares of NASDAQ:TRVN opened at $0.66 on Friday. The company has a market capitalization of $47.17 million, a P/E ratio of -0.54 and a beta of 0.61. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 0.28. Trevena has a 1 year low of $0.55 and a 1 year high of $3.58.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.00 million. As a group, equities analysts predict that Trevena will post -0.55 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Northern Trust Corp boosted its position in Trevena by 6.6% in the first quarter. Northern Trust Corp now owns 579,697 shares of the biopharmaceutical company’s stock valued at $950,000 after buying an additional 35,967 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Trevena by 635.7% in the first quarter. JPMorgan Chase & Co. now owns 89,228 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 77,100 shares in the last quarter. LMR Partners LLP acquired a new stake in Trevena in the second quarter valued at approximately $207,000. GSA Capital Partners LLP boosted its position in Trevena by 186.2% in the second quarter. GSA Capital Partners LLP now owns 351,847 shares of the biopharmaceutical company’s stock valued at $507,000 after buying an additional 228,900 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new stake in Trevena in the second quarter valued at approximately $411,000. Hedge funds and other institutional investors own 42.33% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/10/trevena-inc-trvn-short-interest-update.html.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Recommended Story: How are the companies in the S&P 500 selected?

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply